Condition: Chronic Lymphocytic Leukaemia (CLL) · Multiple Myeloma (MM) · Secondary Immunodeficiency (SID) · Sponsor: Medical University Innsbruck
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections. The study focuses on adults diagnosed with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who are at increased risk of infections due to SID. The main questions it aims to answer are: 1. Can a newly developed PRO screening tool for infection-related symptoms reliably detect infections in patients with SID? 2. How does the health-related quality of life change over the treatment course Participants will: * Complete daily electronic PRO questionnaires (ePRO) to monitor infection-related symptoms * Complete ePRO health-related quality of life questionnaires every 1.5 months * Participate in study visits every three months to ensure documentation of clinical data
This description comes directly from the study's public registry record.
Jens Lehmann, Ph.D. · +43 50 504 81551 · jens.lehmann@i-med.ac.at
Jan-Paul Bohn, Dr. · +43 50 504 82916 · jan-paul.bohn@i-med.ac.at
Always discuss trial participation with your own doctor first.
| Medizinische Universität Innsbruck | Innsbruck, Tyrolia, Austria | Recruiting |
| Medizinische Universität Graz | Graz, Austria | Not Yet Recruiting |
| BKH Kufstein | Kufstein, Austria | Not Yet Recruiting |
| Onkologischer Schwerpunkt am Oskar-Helene-Heim | Berlin, Germany | Not Yet Recruiting |
| Klinikum Garmisch-Partenkirchen | Garmisch-Partenkirchen, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06821880